Review Reports
- Isabel Krug 1,*,
- An Binh Dang 1,2,3 and
- Ying Qing Won 1
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for Authors
The manuscript under review addresses a highly topical and emerging area of research concerning the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact on eating disorders and related psychological and behavioral processes. While the topic is certainly relevant and of interest within the broader fields of nutrition, metabolism, and clinical psychology, the contribution of this narrative review to the field remains limited by several key factors that significantly reduce its suitability for publication in a journal of Nutrients' standing.
First and foremost, the review lacks a systematic approach in the selection and analysis of the literature, relying instead on a narrative synthesis that, while broad in scope, lacks the rigor, objectivity, and reproducibility characteristic of high-quality systematic reviews or meta-analyses. This methodological limitation results in a manuscript that presents a somewhat fragmented overview of the topic, without providing clear answers or insights into the causal mechanisms, efficacy, or safety of GLP-1RAs in the context of various eating disorders. The absence of well-founded quantitative data and critical appraisal of study designs undermines the scientific robustness of the conclusions drawn.
Furthermore, the manuscript tends to emphasize theoretical and psychosocial considerations such as stigma, social media influence, and equity issues more prominently than it addresses clinically actionable information. While these are important dimensions, their presentation is not sufficiently integrated with clinical evidence or translational research insights, which leaves the overall narrative feeling speculative rather than evidence-based. The review does not sufficiently distill practical recommendations or guidelines that could inform clinical decision-making or nutritional management for patients receiving GLP-1RAs, especially those with or at risk for eating disorders.
The discussion of the current evidence base reveals substantial gaps, many of which the authors acknowledge, including the paucity of high-quality randomized controlled trials, the limited longitudinal data, and the incomplete understanding of neurobiological pathways involved. However, the manuscript stops short of offering a clear research agenda or strategic framework to address these gaps, which diminishes its value as a guiding document for future studies.
In addition, while the reference list is comprehensive and includes recent studies, the review would benefit from a more focused critical evaluation of the highest quality evidence. Many cited studies are small-scale, preliminary, or observational in nature, and their limitations are not sufficiently highlighted in the text. This absence of a critical lens risks overestimating the strength and applicability of the findings.
Finally, the manuscript’s language is clear and accessible, posing no significant barrier to understanding. However, the overall tone and structure could be improved to enhance coherence and impact by narrowing the scope and sharpening the focus on clinically relevant themes and evidence-based conclusions.
Given these considerations, the manuscript in its current form does not meet the standards required for publication in Nutrients. It is recommended that the authors undertake a substantial revision, incorporating a more systematic literature review methodology, emphasizing high-quality evidence, critically appraising existing studies, and clearly delineating implications for clinical practice and future research directions. This would greatly improve the scientific rigor and potential impact of the work.
Author Response
See comments and responses attached.
Author Response File:
Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for Authors
In this narrative review, the authors provide a very interesting and timely overview of one of the hot topics today, the use of GLP-1RAs, integrating biological, psychological, and sociocultural perspectives. A new intersection between metabolic treatment and mental health is addressed, highlighting important implications for research on eating disorders and clinical care.
I believe that some minor revisions are necessary prior to publication to improve its clarity.
- The abstract is exhaustive and summarises the key points well; however, some sentences are rather long and dense, making it less readable (e.g. lines 17-19; 25-28). I suggest considering minor stylistic changes, such as breaking up some complex sentences or simplifying their structure, to improve the flow and make the text more accessible to readers.
- I suggest standardising the formatting of the abstract: currently, only the “Background/Objectives” section is in bold. For greater clarity and consistency, it would be useful to also put the other main sections (“Methods”, “Results” and “Conclusions”) in bold. This small change will improve the readability and overall structure of the abstract.
- Line 44 – The expression “cardiometabolic outcomes” and “metabolic benefits” is redundant, as metabolic benefits are already implied in cardiometabolic outcomes. I suggest removing or rephrasing “metabolic benefits” to lighten the sentence.
- Lines 48-49: the concepts of binge eating and emotion-driven eating overlap significantly. Many people experiencing binge eating usually do so in response to negative emotions. Without clarifying the difference, the two terms may seem repetitive. It would be helpful to clarify whether “binge eating” refers to a clinically diagnosable disorder (e.g., BED line 81) and “emotion-driven eating” refers to subclinical eating patterns related to emotions, to avoid terminological ambiguity.
- Even though this is a narrative review, the direct reference to Serena Williams and the full title reported by the media seem over-specific and could detract from the broader academic discussion. I recommend generalizing the point about celebrity endorsements and media framing to maintain a consistent academic tone.
- Lines 68-77: although rhetorical questions may be stylistically appropriate in a narrative review, this specific section could benefit from simplification. Grouping similar questions by theme or transforming them into concise research questions could improve readability and impact.
- The last paragraph of the introduction (lines 78-88) provides a clear overview of the topics discussed. However, the level of detail, particularly the subcategories in parentheses, may be excessive for an introductory section. I recommend simplifying the list or summarizing the domains more concisely to improve readability. In addition, the phrase “patient-centered use of GLP-1 usage” at the end is redundant (lines 88-89).
- Line 94: while narrative reviews do not require formal inclusion/exclusion criteria, it can still be useful to clarify whether specific quality thresholds were applied during selection (e.g. peer review status, relevance, or methodological rigor).
- The rationale for including sources in German and Spanish should be briefly explained, particularly if these languages were expected to provide culturally specific insights.
- Section “Appetite and Eating Behaviours”: this section presents a comprehensive and well-documented summary of the physiological and behavioral effects of GLP-1RAs. However, some points could be improved. Several repetitions could be reduced to streamline the narrative; for example, mechanisms related to appetite and reward are discussed multiple times (e.g., lines 119 and 126), as are symptoms (e.g., lines 115 and 134). Furthermore, discussions on pharmacological mechanisms, behavioral effects, side effects, and research limitations are intertwined, making it more difficult to follow the thread of the argument. I suggest reorganizing the section to improve clarity and reader engagement.
- Section “Mental Health and Quality of Life”: this section provides a comprehensive and balanced overview of the impact of GLP-1RAs on mental health, including QoL, depressive symptoms, and suicidality. However, subsections could be created (e.g., 6.1. depression, 6.2 suicidality) to facilitate reading and reinforce the impact of conflicting evidence.
- The sections on costs, inequalities, and use in special populations are very important and well documented, with up-to-date references that reinforce their credibility. The text is clear in its presentation, although in some places it could be made more concise to improve readability. Some terms used to describe overweight or obesity vary within the text: terms such as “higher weight,” “overweightness,” and “larger bodies” are used intermittently. It would be useful to standardize the terminology to avoid ambiguity and improve readability; standardizing them would help avoid confusion. Greater emphasis on the long-term implications of GLP-1RA use in adolescents would be advisable, as would some insight into possible strategies for reducing inequalities in access to these drugs, which are key issues in this discussion. Finally, a small insert highlighting the ethical issues related to disparities in access (e.g., justice, equity, and respect for health rights) could further enrich the section.
- It would be useful to further strengthen the discussion on the methodological limitations of the existing literature, in particular by emphasizing the importance of longitudinal studies and studies with more heterogeneous samples.
- I would encourage the authors to spell out the practical recommendations for clinicians more clearly, in order to effectively translate the evidence into psychological monitoring protocols and multidisciplinary intervention.
Overall, this manuscript provides a significant and well-articulated contribution that enriches the debate on the biopsychosocial implications of GLP-1RAs, offering a useful starting point for future studies and clinical practice.
Author Response
See comments and responses attached.
Author Response File:
Author Response.pdf
Reviewer 3 Report
Comments and Suggestions for Authors
Obesity pharmacotherapy has been experiencing a real breakthrough for several years, and drugs that target GLP-1 receptors are gaining increasing recognition in the fight against excess body weight, although reports of their side effects are increasingly emerging. Therefore, this manuscript is a valuable contribution to the discussion. I congratulate the authors for such a multifaceted approach and discussion of the potential impact of GLP-1RAs.
These drugs are available in various forms, doses, and differ in their route of administration (tablets, injections) and the interval between subsequent doses. Furthermore, in recent years, more advanced forms of agonists have also emerged, such as GLP-1/GIP/glucagon polyagonists, which act on multiple receptors simultaneously, potentially enhancing therapeutic effects (this is worth mentioning in the introduction). For example, Tirzepatide (Mounjaro) – a dual GLP-1 and GIP agonist, is one of the newest drugs used in the treatment of obesity and diabetes. Retatrutide – A triple agonist of GLP-1, GIP, and glucagon, for which we have clinical trial results (e.g., DOI: 10.1056/NEJMoa2301972).
All of these medications share common properties that make them effective in weight loss: they regulate blood glucose levels, reduce appetite, and increase satiety. However, they differ in their potency and impact on health, including mental health.
Therefore, it would be worthwhile to indicate which medications the presented results apply to.
In conclusion, it may also be worth pointing out that, in addition to pharmacological treatment, a change in eating habits, guided by a dietitian and a psychodietitian, is necessary.
Author Response
See comments and responses attached.
Author Response File:
Author Response.pdf
Round 2
Reviewer 1 Report
Comments and Suggestions for Authors
Thank you for your revisions and commitment to improving the manuscript. However, despite the changes made, there are still substantial issues that prevent us from considering the work suitable for publication.
The review remains primarily narrative in nature, with a methodological approach that is not rigorous enough to meet the journal's standards. The absence of a clear systematic strategy in the selection, evaluation and synthesis of studies, together with the prevalent use of preliminary and observational evidence, does not allow for solid or clinically applicable conclusions to be drawn on the topic covered.
The added sections improve the structure, but do not address the basic methodological shortcomings or the limited ability to guide clinical practice or future research with a truly critical approach based on robust evidence. There also remains an excessive speculative component with regard to clinical implications, which is not supported by comparable, standardised or good-quality data.
In light of the above, the manuscript does not meet the required levels of scientific rigour and original contribution and cannot be accepted in its current form.
Author Response
Comment: Thank you for your revisions and commitment to improving the manuscript. However, despite the changes made, there are still substantial issues that prevent us from considering the work suitable for publication.
The review remains primarily narrative in nature, with a methodological approach that is not rigorous enough to meet the journal's standards. The absence of a clear systematic strategy in the selection, evaluation and synthesis of studies, together with the prevalent use of preliminary and observational evidence, does not allow for solid or clinically applicable conclusions to be drawn on the topic covered.
The added sections improve the structure, but do not address the basic methodological shortcomings or the limited ability to guide clinical practice or future research with a truly critical approach based on robust evidence. There also remains an excessive speculative component with regard to clinical implications, which is not supported by comparable, standardised or good-quality data.
In light of the above, the manuscript does not meet the required levels of scientific rigour and original contribution and cannot be accepted in its current form.
Response: Thank you very much for sharing the reviewer’s further comments and for the opportunity to clarify our approach. We appreciate the reviewer’s continued engagement with our manuscript. However, many of the concerns raised—particularly regarding the request for a systematic review—have already been addressed in our previous revision to the fullest extent that the current evidence base allows.
We would also like to note that the other two reviewers evaluated the revised manuscript positively and expressed satisfaction with the improvements made. The divergence in Reviewer 1’s perspective therefore appears to reflect methodological expectations that are not aligned with the current state of the evidence base.
In that context, we would like to reiterate respectfully and transparently why a systematic review is not feasible at this stage.
Why a systematic review is not possible at this time
- Only a very small number of empirical studies examine GLP-1RA use in relation to eating disorders (EDs) or psychological outcomes, with several ED subtypes lacking empirical data altogether. A systematic review requires a minimum study base to justify structured searching, quality appraisal, and synthesis; this threshold is not met.
- Existing studies vary widely in population, methodology, outcome measures, study design, and medication type (including single vs dual agonists, oral vs injectable, varying doses). This violates the assumptions required for systematic synthesis or meta-analysis and would result in a methodologically meaningless review.
- Most available evidence consists of preliminary, observational, single-arm, or cross-sectional studies that do not permit standardised evaluation or comparative synthesis. Without comparable outcome metrics, systematic review methods become inappropriate.
- This research area is emerging quickly, with early-stage evidence scattered across diverse disciplines. In such contexts, high-quality journals—including Nutrients—routinely publish narrative reviews to consolidate early findings until the evidence base matures sufficiently for systematic methods.
- Forcing a systematic approach at this early stage could inflate the perceived strength of the evidence and misrepresent the substantial gaps in the field.
How we addressed this concern in the previous revision
In our prior revision, we directly and comprehensively addressed these issues by:
- Clearly explaining why a systematic review is not currently feasible.
- Detailing our search strategy, inclusion/exclusion criteria, and justification for adopting a narrative approach.
- Adding a dedicated subsection discussing the methodological limitations of narrative reviews.
- Strengthening critical appraisal of the existing studies, explicitly emphasising their preliminary and observational nature.
- Clarifying that all conclusions are preliminary, cautious, and hypothesis-generating.
- Explicitly stating that systematic reviews and meta-analyses will become essential once sufficient studies exist.
We believe that these revisions substantially improved the manuscript’s transparency and methodological clarity—improvements that were recognised by the other two reviewers.
Given that the remaining concerns reflect a methodological expectation that is not feasible for this field at present, and considering that two of the three reviewers have endorsed the quality and relevance of the revised manuscript, we respectfully request the guidance from Nutrients on how best to proceed.
Specifically, we would appreciate your advice on:
- Whether Nutrients is willing to consider high-quality narrative reviews in areas where a systematic review is methodologically inappropriate, and
- How we might address Reviewer 1’s expectations within the limitations of the current literature base.
We remain committed to further strengthening the manuscript within the bounds of what the evidence allows and appreciate your continued guidance.
Thanks so much for your help.
On behalf of all the authors